320 related articles for article (PubMed ID: 26275578)
1. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.
Keats J; Micallef M; Grebely J; Hazelwood S; Everingham H; Shrestha N; Jones T; Bath N; Treloar C; Dore GJ; Dunlop A;
Int J Drug Policy; 2015 Oct; 26(10):999-1006. PubMed ID: 26275578
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia.
Treloar C; Rance J; Bath N; Everingham H; Micallef M; Day C; Hazelwood S; Grebely J; Dore GJ
Int J Drug Policy; 2015 Oct; 26(10):992-8. PubMed ID: 25697089
[TBL] [Abstract][Full Text] [Related]
3. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.
Alavi M; Grebely J; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ;
Clin Infect Dis; 2013 Aug; 57 Suppl 2():S62-9. PubMed ID: 23884068
[TBL] [Abstract][Full Text] [Related]
4. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.
Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L
J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080
[TBL] [Abstract][Full Text] [Related]
5. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals.
Treloar C; Newland J; Rance J; Hopwood M
J Viral Hepat; 2010 Dec; 17(12):839-44. PubMed ID: 20070504
[TBL] [Abstract][Full Text] [Related]
6. The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics.
Rance J; Newland J; Hopwood M; Treloar C
Soc Sci Med; 2012 Jan; 74(2):245-53. PubMed ID: 22133583
[TBL] [Abstract][Full Text] [Related]
7. Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection.
Crawford S; Bath N
Clin Infect Dis; 2013 Aug; 57 Suppl 2():S75-9. PubMed ID: 23884070
[TBL] [Abstract][Full Text] [Related]
8. How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting.
Treloar C; Rance J;
Int J Drug Policy; 2014 Sep; 25(5):865-70. PubMed ID: 24559604
[TBL] [Abstract][Full Text] [Related]
9. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study.
Grebely J; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Phung N; Weltman MD; Day CA; Treloar C; Bath N; Haber PS; Dore GJ;
Addiction; 2016 Feb; 111(2):311-9. PubMed ID: 26451534
[TBL] [Abstract][Full Text] [Related]
10. Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study.
Treloar C; Rance J; Dore GJ; Grebely J;
J Viral Hepat; 2014 Aug; 21(8):560-7. PubMed ID: 24299222
[TBL] [Abstract][Full Text] [Related]
11. Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia.
Treloar C; Rance J; Grebely J; Dore GJ
Drug Alcohol Depend; 2013 Dec; 133(2):529-34. PubMed ID: 23932843
[TBL] [Abstract][Full Text] [Related]
12. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network.
Morris L; Smirnov A; Kvassay A; Leslie E; Kavanagh R; Alexander N; Davey G; Williams O; Gilks C; Najman J
Int J Drug Policy; 2017 Sep; 47():216-220. PubMed ID: 28666635
[TBL] [Abstract][Full Text] [Related]
13. Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV).
Fadnes LT; Aas CF; Vold JH; Ohldieck C; Leiva RA; Chalabianloo F; Skurtveit S; Lygren OJ; Dalgård O; Vickerman P; Midgard H; Løberg EM; Johansson KA;
BMC Infect Dis; 2019 Nov; 19(1):943. PubMed ID: 31703669
[TBL] [Abstract][Full Text] [Related]
14. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs.
Treloar C; Hull P; Dore GJ; Grebely J
Drug Alcohol Rev; 2012 Nov; 31(7):918-24. PubMed ID: 22612899
[TBL] [Abstract][Full Text] [Related]
15. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.
Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J
Clin Infect Dis; 2021 Jul; 73(1):e69-e78. PubMed ID: 32421194
[TBL] [Abstract][Full Text] [Related]
16. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.
Bruggmann P; Grebely J
Int J Drug Policy; 2015 Feb; 26 Suppl 1():S22-6. PubMed ID: 25245939
[TBL] [Abstract][Full Text] [Related]
17. Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: the ETHOS study.
Alavi M; Micallef M; Fortier E; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Grebely J;
J Viral Hepat; 2015 Nov; 22(11):914-25. PubMed ID: 25996567
[TBL] [Abstract][Full Text] [Related]
18. 'Beyond the willing & the waiting' - The role of peer-based approaches in hepatitis C diagnosis & treatment.
Henderson C; Madden A; Kelsall J
Int J Drug Policy; 2017 Dec; 50():111-115. PubMed ID: 28927831
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.
Graf C; Mücke MM; Dultz G; Peiffer KH; Kubesch A; Ingiliz P; Zeuzem S; Herrmann E; Vermehren J
Clin Infect Dis; 2020 May; 70(11):2355-2365. PubMed ID: 31513710
[TBL] [Abstract][Full Text] [Related]
20. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
